Fasting and Post Prandial Monitoring of Dipeptidyl Peptidase-IV (DPP-IV) - A Biomarker to Assess Incretin Response in Type-2 Diabetes
DOI:
https://doi.org/10.3329/sjps.v2i2.1698Keywords:
Type 2 diabetes, metformin, DPP-IV, HbA1c, GLP-1Abstract
Dipeptidyl peptidase-IV (DPP-IV) could serve as a potential biomarker in monitoring the diseaseprogression and improvement on treatment. To investigate fasting & post prandial response of
DPP-IV enzyme as indirect marker of incretin response failure after chronic treatment with
metformin in type 2 diabetes. The study included twelve nondiabetic subjects, ten patients with
glycosylated hemoglobin values (6-8%) and fifteen patients with glycosylated hemoglobin greater
than 8 % of type-2 diabetes patients of either sex with metformin treatment above 3 years were
recruited. Fasting and post prandial DPP-IV levels were calculated. HbA1c was used to assess
diabetes status. DPP-IV activity (fasting) in type 2 diabetic subjects with HbA1c > 8 % was
significantly higher DPP-IV (44.67 ± 2.19 U/l) than in non diabetic subjects (24.39 ± 3.97 U/l). A
significant correlation between DPP-IV (fasting / post prandial) and HbA1c (r = 0.821 & r = 0.732,
P< 0.01) was observed in both diabetic (HbA1c 6-8, HbA1c < 8) patients. Hyperglycemia induces
significant increase in serum DPP-IV activity in fasting condition and might contribute to the
reduction in active glucagon like peptide-1(GLP-1) in type 2 diabetic subjects. In normal subjects
during post prandial condition, there is sudden increase followed by decrease of GLP-1 due to
cleavage of GLP-1 to as substrate of DPP-IV is seen as upsurge of DPP-IV. This response was
lacking in diabetic patients with high HbA1c indicates indirectly metformin failure to secrete GLP-1.
High fasting level and decreased post prandial of DPP-IV may indicate drug failure in type-2
diabetes mellitus.
Key words: Type 2 diabetes; metformin; DPP-IV; HbA1c; GLP-1.
DOI: 10.3329/sjps.v2i2.1698
Stamford Journal of Pharmaceutical Sciences Vol.2(2) 2009: 81-85
Downloads
113
57
Downloads
Published
How to Cite
Issue
Section
License
As a condition of publication, all authors must transfer copyright to the Department of Pharmacy. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur in the submission, and that the final version of the manuscript has been seen and approved by them.Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.
